GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (GREY:VNAPF) » Definitions » Cyclically Adjusted Price-to-FCF

Verona Pharma (Verona Pharma) Cyclically Adjusted Price-to-FCF : (As of May. 25, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Verona Pharma Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Verona Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Verona Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Cyclically Adjusted Price-to-FCF Chart

Verona Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Verona Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Verona Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Verona Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verona Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verona Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Verona Pharma's Cyclically Adjusted Price-to-FCF falls into.



Verona Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Verona Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Verona Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.028/131.6000*131.6000
=-0.028

Current CPI (Mar. 2024) = 131.6000.

Verona Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201206 0.000 95.600 0.000
201212 0.000 97.300 0.000
201306 0.000 98.000 0.000
201312 0.000 99.200 0.000
201406 0.000 99.800 0.000
201412 0.000 99.900 0.000
201506 0.000 100.100 0.000
201512 0.000 100.400 0.000
201606 0.000 101.000 0.000
201609 0.000 101.500 0.000
201612 0.000 102.200 0.000
201703 -0.087 102.700 -0.111
201706 -0.071 103.500 -0.090
201709 -0.101 104.300 -0.127
201712 -0.065 105.000 -0.081
201803 -0.085 105.100 -0.106
201806 -0.070 105.900 -0.087
201809 -0.009 106.600 -0.011
201812 -0.057 107.100 -0.070
201903 -0.123 107.000 -0.151
201906 -0.096 107.900 -0.117
201909 -0.081 108.400 -0.098
201912 -0.108 108.500 -0.131
202003 -0.125 108.600 -0.151
202006 -0.029 108.800 -0.035
202009 -0.029 109.200 -0.035
202012 -0.041 109.400 -0.049
202103 -0.040 109.700 -0.048
202106 -0.043 111.400 -0.051
202109 0.048 112.400 0.056
202112 -0.036 114.700 -0.041
202203 -0.030 116.500 -0.034
202206 -0.041 120.500 -0.045
202209 -0.038 122.300 -0.041
202212 -0.016 125.300 -0.017
202303 -0.012 126.800 -0.012
202306 -0.044 129.400 -0.045
202309 -0.026 130.100 -0.026
202312 -0.022 130.500 -0.022
202403 -0.028 131.600 -0.028

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Verona Pharma  (GREY:VNAPF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Verona Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Verona Pharma (Verona Pharma) Business Description

Industry
Traded in Other Exchanges
Address
3 More London Riverside, London, GBR, SE1 2RE
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.